NAV3 and cancer: The LOH method used in this study, would not by itself have excluded such an interpretation as changes close to the location of the NAV3 gene (for example, the cancer implicated gene E2F7 (Endo-Munoz et al, 2009)) would also have shown loss of heterogeneity in this assay.